Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04485286 · ClinicalTrials.gov registry record · Phase 2
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
A Phase 2 study of Lung Cancer and Pancreas Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT04485286 is a Phase 2 study of Lung Cancer and Pancreas Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 72 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04485286, a Phase 2 study of Lung Cancer and Pancreas Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.
Conditions Studied
Interventions
- DRUG [68Ga]CBP8
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2020-07-19 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04485286
The ClinicalTrials.gov registry entry for NCT04485286 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which [68Ga]CBP8 is the first listed.
NCT04485286 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04485286 about?
NCT04485286 is a clinical study titled "Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury". The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.
What is the current status of trial NCT04485286?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2020-07-19. Estimated completion is 2027-07.
What conditions does trial NCT04485286 study?
This clinical trial studies the following conditions: Lung Cancer, Pancreas Cancer, Radiation-Induced Lung Injury, Radiation Fibrosis.
What interventions are being tested in trial NCT04485286?
The interventions under investigation include: [68Ga]CBP8 (DRUG).
Who is sponsoring clinical trial NCT04485286?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04485286 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.